Samsung Biologics clears tender threshold for peptide maker PolyPeptide
Shareholders submitted 87.88% of targeted shares at 44.31 Swiss francs each, well above the 66.7% minimum, with closing expected by the end of next month.
The wire
- 01Samsung Biologics said 29,014,418 shares were tendered through its Samsung Peptide vehicle, including the entire 18,375,000-share stake of largest holder Draupnir, clearing the 66.7% minimum acceptance condition.
- 02PolyPeptide is a major peptide CDMO, so ownership change affects contract manufacturing capacity for peptide drug developers and incretin supply chains.
- 03An additional submission period runs from the 19th to the 30th and the deal still requires regulatory approvals in Europe, India, Australia, Brazil and elsewhere before payment.
From the source
Read at mt.co.krSamsung Biologics meets minimum tender offer condition for PolyPeptide, acquisition to close next month
Samsung Biologics meets minimum tender offer condition for PolyPeptide, acquisition to close next month
